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to bone marrow-derived stromal (MdS) cells. The bone marrow
mesenchyme supports hematopoietic stem cells and progenitors in
vivo and in vitro. The AdS are readily accessible from subcutaneous
fat but have not been fully characterized for hematopoietic sup-
port. We now directly compare the relative capacities of allogeneic
AdS and MdS to support hematopoiesis. In total, 4 preparations of
AdS and 4 preparations of MdS were used to complete these
studies. Support for primitive hematopoietic progenitors was mon-
itored in 5-week long-term culture (LTC) assays. CD34CD38neg
cells were puriﬁed from umbilical cord blood (UCB, n  8) to
establish duplicate cultures with 100 hematopoietic progenitors per
well in standard Dexter-type media. LTC cultures on MdS gave
rise to 67.1  19.8 CFU after 5 weeks. Parallel cultures on AdS
gave rise to 26.6  11.4 CFU. These frequencies approach statis-
tical signiﬁcance (p  0.054). Importantly, however, 30% of the
cultures initiated on AdS failed to support LTC. Thus, 100 CD34
CD38neg cells may deﬁne a limit-dilution for LTC activity on AdS
cells. In contrast, all cultures initiated on MdS supported LTC. In
shorter-term assays, parallel cultures were established using 10,000
CD34 linneg UCB cells for 12 days. The cultures were established
in DMEM/F12 media containing 10% serum. No exogenous cy-
tokines were used. The results are tabulated below. AdS and MdS
supported similar expansions of total hematopoietic (CD45) cells.
However, cultures established on MdS maintained higher percent-
ages of CD34 cells over the 12 day time course. Not surprisingly,
there was a strong association between the percentages of CD34
cells and the frequencies of CFU present at day 12 (AdS, r  0.81;
MdS, r  0.85). However, without exogenous cytokines these
stroma maintained but did not expand the total content of CFU.
Finally, both AdS and MdS encouraged the outgrowth of lymphoid
progenitors as monitored by the presence of CD7 CD34neg cells
as well as by the growth of NK (CD56) cells in secondary
cultures. Higher percentages of CD7 cells were noted on AdS
than on MdS. In total, these data suggest that AdS and MdS
provide similar hematopoietic support, although subtle distinctions
were noted. These studies provide a model that can be manipulated
to optimize hematopoietic expansion ex vivo.
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THROMBOTIC MICROANGIOPATHY (TMA) FOLLOWING ALLOGENEIC
STEM-CELL TRANSPLANTATION (SCT) IN THE ERA OF REDUCED-IN-
TENSITY CONDITIONING: THE INCIDENCE IS NOT REDUCED
Shimoni, A.1, Hardan, I.1, Yeshurun, M.1, Avigdor, A.1, Papatrypho-
nos, A.2, Tsolakis, F.I.3, Nagler, A.1 1. Chaim Sheba Medical Center,
Tel-Hashomer, Israel; 2. Archbishop Makarios III, Nicosia, Cyprus; 3.
Limassol General Hospital, Limassol, Cyprus
TMA is one of the most severe complications of SCT. Endothe-
lial cell injury caused by the toxic effects of high-dose chemo-
radiotherapy is likely the primary event in the pathogenesis. The
incidence, clinical settings, and risk factors for TMA in the era of
nonmyeloablative and reduced intensity conditioning (NST/RIC)
have not been well deﬁned. We collected data on 147 consecutive
SCTs for various hematologic malignancies. The diagnosis of
TMA required thrombocytopenia, elevated LDH level and frag-
mented red cells in peripheral blood ﬁlm. TMA occurred following
22 SCTs with a projected incidence of 20  4% in a median of 30
days after SCT. TMA occurred in 3 overlapping clinical settings:
classical multifactorial TMA, TMA associated with severe hepatic
GVHD, and TMA associated with second allogeneic SCT, with a
projected incidence of 8  3%, 73  14%, and 70  16% of pts
at risk, respectively. TMA occurred following 23  6% of NST/
RIC (14 of 84) and 16  5% of myeloablative conditioning (8 of
63) (p NS). Univariant analysis determined SCT from unrelated
donors, SCT during advanced/ active disease, second SCT within
6 months of a prior SCT, and acute GVHD as risk factors for
TMA. The last two factors remained signiﬁcant in a multivariant
model with hazard ratios of 6.4 and 14.5, respectively. Therapy
included withdrawal or reduction of cyclosporine dose and infusion
of cryoprecipitate poor plasma with a response rate of 23 percent.
4 of the non-responders were treated with plasma exchange and 2
responded. Overall, 32% of pts responded to any line of therapy.
Only 4 pts are currently alive. Ten died of complications related to
acute GVHD. Five died of bleeding complications; 4 of diffuse
alveolar hemorrhage (DAH) and one of CNS bleeding. One pt
died of cerebral TMA with refractory convulsions. The peri-TMA
mortality rate was 68  10%. Two additional pts later died of
relapse. SCT-associated TMA is a relatively common complication
with unsatisfactory therapy and grim prognosis. Fludarabine-based
NST/RIC does not confer a lesser risk for TMA. This unexpected
observation relates in part to the selective use of NST/RIC in older
pts, pts having a second SCT, extensive prior therapy or unrelated
donor SCT, all risk factors for TMA. Fludarabine, a major con-
stitute of these regimens, may also be involved in causing endo-
thelial damage and increasing the risk for TMA. Further explora-
tion of novel preventive and therapeutic measurements is required
in high-risk settings.
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EVALUATION OF THE PLATELET-SPECIFIC ANTIBODY RESPONSE IN
THROMBOCYTOPENIA FOLLOWING ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Yamazaki, R.1,2, Mori, T.1, Kuwana, M.2, Okazaki, Y.2, Kawakami,
Y.2, Ikeda, Y.1, Okamoto, S.1 1. Division of Hematology, Department of
Internal Medicine; 2. Division of Cellular Signaling, Institute for Ad-
vanced Medical Research, Keio University School of Medicine, Shinjuku-
ku, Tokyo, Japan
Thrombocytopenia is a common complication early and late after
allogeneic hematopoietic stem cell transplantation (allo-HSCT),
but its etiologies are largely unknown. In this study, a role of
anti-platelet antibody response in patients with thrombocytopenia
after allo-HSCT was examined by detecting antibodies to glyco-
protein IIb/IIIa (GPIIb/IIIa), a major platelet-speciﬁc autoantigen
in patients with idiopathic thrombocytopenic purpura (ITP). Fifty-
six patients with hematological malignancies who received allo-
HSCT were enrolled. Of these, 35 patients suffered from pro-
longed thrombocytopenia. As controls, 78 ITP patients and 52
healthy donors were also examined. Circulating B cells secreting
anti-GPIIb/IIIa antibodies were measured using enzyme-linked
immunospot assay, and anti-GPIIb/IIIa antibodies in platelet elu-
ates and plasma were detected by enzyme-linked immunosorbent
assay. Frequency of anti-GPIIb/IIIa antibody-producing B cells in
allo-HSCT patients was comparable to that in ITP patients, but
was signiﬁcantly higher than that in healthy donors (5.8  6.4 vs
8.2  5.4 and 0.4  0.3 /105PBMCs; p  0.02 and 0.001,respec-
tively). In allo-HSCT patients, anti-GPIIb/IIIa antibody-produc-
ing B cell frequency was signiﬁcantly greater in patients with
thrombocytopenia than in those without (7.3  7.3 vs 3.3  3.6;
p  0.009). Moreover, platelet count was negatively correlated
with anti-GPIIb/IIIa antibody-producing B cell frequency (r 0.3,
p  0.005). Of 18 platelet eluate samples, 13 had a detectable level
of anti-GPIIb/IIIa antibodies, whereas plasma anti-GPIIb/IIIa an-
tibodies were undetectable in all cases. Serial analysis of a patient
with thrombocytopenia who responded to corticosteroid therapy
Table. Hematopoietic Support in Short-term Culture
CD45
Cell
Expansion
Percent
CD34,
Day 12
CFU/100
Input
Cells
CFU
Expansion
Percent
CD7,
Day 12
AdS 3.78  1.1
fold
17.4  5.1
%
12.2  2.8
CFU
0.90  0.3
fold
28.6  5.6
%
MdS 3.4  1.3
fold
28.7  6.5
%
16.3  3.7
CFU
1.07  0.27
fold
19.5  4.2
%
P 0.127 0.002 0.062 0.366 0.003
n 8 8 8 8 6
Values reported are the average  SEM, P values are by t-test.
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